Rosenberg Eli S, Millett Gregorio A, Sullivan Patrick S, Del Rio Carlos, Curran James W
Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, USA (E Rosenberg PhD, Prof P Sullivan PhD, Prof J Curran MD); amfAR, The Foundation for AIDS Research, Washington DC, USA (G Millett MPH); Hubert Department of Global Health, Emory University Rollins School of Public Health and Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, USA (Prof C del Rio MD).
Lancet HIV. 2014 Dec;1(3):e112-e118. doi: 10.1016/S2352-3018(14)00011-3.
Black/white disparities in HIV incidence and prevalence among men who have sex with men (MSM) in the United States remain largely unexplained. We examined the impact on HIV prevalence and incidence of interventions that decrease disparities in HIV care. Deciding which interventions have most impact on reducing disparities is critical.
Using available US Centers for Disease Control and Prevention (CDC) estimates, we constructed HIV care continua for black and white MSM for 2009-2010. These estimates were used as parameters in a deterministic model to yield estimated race-specific transmissions, transmission rates, incidence rates, and rate-ratios (RR). We examined the impact of changes in the care continuum for black MSM on transmission and incidence rates.
Marked disparities were found throughout the care continuum: ultimately, 16% of black and 34% of white MSM achieved viral suppression. Based on these care continua, 9,833 and 9,710 new HIV transmissions were estimated annually respectively from HIV-positive black and white MSM (transmission RR=1·36 and incidence RR=7·92). In a model where black and white MSM have identical care outcomes, transmission RR=1·00 and incidence RR=5·80. Scenarios of 95% diagnosis, 95% retention, and concurrent 95% diagnosis and 95% retention respectively yield transmission RR=1·00, 1·02, 0·56, and incidence RR=5·81, 5·93, 3·28.
Disparities in HIV transmission rates may be reduced by improving the HIV care continuum outcomes, but existing racial disparities in HIV prevalence will likely continue to drive higher incidence among black MSM for decades to come.
美国男男性行为者(MSM)中,黑人与白人在艾滋病毒发病率和流行率方面的差异在很大程度上仍无法解释。我们研究了减少艾滋病毒治疗差异的干预措施对艾滋病毒流行率和发病率的影响。确定哪些干预措施对减少差异影响最大至关重要。
利用美国疾病控制与预防中心(CDC)的现有估计数据,我们构建了2009 - 2010年黑人和白人男男性行为者的艾滋病毒治疗连续体。这些估计数据被用作确定性模型的参数,以得出按种族划分的估计传播率、传播速率、发病率和率比(RR)。我们研究了黑人男男性行为者治疗连续体的变化对传播率和发病率的影响。
在整个治疗连续体中发现了明显差异:最终,16%的黑人男男性行为者和34%的白人男男性行为者实现了病毒抑制。基于这些治疗连续体,估计每年分别有9833例和9710例新的艾滋病毒传播来自艾滋病毒阳性的黑人和白人男男性行为者(传播RR = 1.36,发病率RR = 7.92)。在一个黑人和白人男男性行为者具有相同治疗结果的模型中,传播RR = 1.00,发病率RR = 5.80。分别为95%诊断率、95%留存率以及同时具备95%诊断率和95%留存率的情景下,传播RR分别为1.00、1.02、0.56,发病率RR分别为5.81、5.93、3.28。
改善艾滋病毒治疗连续体的结果可能会降低艾滋病毒传播率方面的差异,但现有的艾滋病毒流行率种族差异在未来几十年可能会继续导致黑人男男性行为者中发病率更高。